Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

John Davis

Writer

London, U.K
A journalist and editor for more than 30 years, John has a broad interest in pharmaceuticals-related health care policy and breakthroughs in scientific and medical research.  He has degrees in biology and biochemical pharmacology.

Latest From John Davis

Jardiance Drives Boehringer Ingelheim Through First Half, Market Volatility Expected To Continue

Boehringer Ingelheim’s sales were driven by Jardiance and Ofev in the first half of 2020, with contract manufacturing contributing with a 16% increase in sales; more details from the EMPEROR-Reduced Phase III study in heart failure are expected at this month’s European College of Cardiology meeting.

Sales & Earnings Commercial

Pipeline Watch: Phase III Starts With AL001, Beremagene Geperpavec And Relacorilant

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

GlaxoSmithKline Spotlights Immune System And Oncology R&D

New oncology and immunology products are moving rapidly through GSK’s refocused research pipeline, including new agents for multiple myeloma, endometrial and head and neck cancer, adding to efforts against COVID-19, respiratory syncytial virus infection and HIV/AIDS.

ImmunoOncology Research and Development Strategies

GSK Vaccine Sales Hit By COVID-19 But Initial Signs Of Recovery

GlaxoSmithKline sees initial signs of recovery from the coronavirus pandemic in terms of vaccination rates and highlights its growing research progress against COVID, RSV and meningitis, although a UK expert warns against over-optimism.

Sales & Earnings Vaccines

Vico Therapeutics' RNA Modulators For Neurological Diseases Attract Series A Funding

A Netherlands start-up Vico Therapeutics could start clinical trials in late 2021 with its antisense approach to the treatment of rare neurological diseases, financed by its large Series A.

Financing Neurology

Pipeline Watch: Phase III Readouts For Mirakizumab, BXCL501, Rinvoq

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All
UsernamePublicRestriction

Register